PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session

Author's Avatar
May 17, 2021

PhaseBio+Pharmaceuticals%2C+Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today highlighted real-world evidence presented over the weekend at The American College of Cardiology's 70th Annual Scientific Session.